GleneaglesCRC and SCIREX Corporation to Collaborate on Global Clinical Trials
GleneaglesCRC Pte Ltd and SCIREX Corporation announced today that they have signed a Memorandum of Understanding (MOU) outlining the basis for GleneaglesCRC and SCIREX to evaluate their entry into a long-term relationship to collaborate on clinical research services in Asia (excluding India).
Singapore/Horsham, PA (PRWEB) September 19, 2005
GleneaglesCRC Pte Ltd, a wholly owned subsidiary of Parkway Group Healthcare Pte Ltd, and SCIREX Corporation, a wholly owned subsidiary of the Omnicom Group, announced today that they have signed a Memorandum of Understanding (MOU) outlining the basis for GleneaglesCRC and SCIREX to evaluate their entry into a long-term relationship to collaborate on clinical research services in Asia (excluding India). The MOU was signed at GleneaglesCRC's headquarters in Singapore during a recent visit by Douglas Baum, Head of Commercialization & Strategy (Clinical Site Operations) for SCIREX.
Conducting clinical trials in Asia offers a number of advantages, including a relatively lower trial cost per patient compared to the U. S. and Europe, a wider coverage of ethnic population, access to an extensive patient and knowledgeable investigator pool, and above all, the ability to focus on therapies for local diseases.
"The increasing interest shown by our clients toward conducting research in Asia has driven us to search for a potential partnership with a world class CRO like GleneaglesCRC," stated James Utterback, SCIREX CEO. "GleneaglesCRC's combination of local knowledge and understanding of international research standards gives SCIREX a great opportunity to continue to expand its broadening global reach."
"We are excited at the opportunities a collaboration with a leading CRO like SCIREX presents," stated Lance Eminger, Senior Business Development Manager for GleneaglesCRC. "Not only does this relationship allow both companies to compete for research projects at a global level, it will also provide Asian patients and doctors leading edge investigational therapies that they otherwise might not have access to. GleneaglesCRC prides itself on its role in contributing to the improvement of health care options in Asia, and as a result of this cooperation with SCIREX, we expect that role to grow."
About SCIREX
SCIREX Corporation (www. scirex. com) is an industry leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industry. SCIREX possesses capabilities in clinical trial management, drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistics, medical writing and offers an array of technology solutions. SCIREX has experience from more than 1,000 clinical trials involving well over 130,000 patients, in pain and inflammation, neurological and psychiatric disorders, infectious diseases and gastrointestinal and cardiovascular indications. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc. (NYSE: OMC) (www. omnicomgroup. com). Omnicom is a leading global advertising, marketing and corporate communications company.
About GleneaglesCRC
GleneaglesCRC Pte Ltd (www. gleneaglescrc. com) is the Singapore based research arm of one of the largest private health care providers in Asia, Parkway Group Healthcare (www. pgh. com. sg) (SGX: PGH). Since 1999, GleneaglesCRC has functioned as a purely Asian Contract Research Organization (CRO) having regional offices in Singapore, Beijing, Shanghai, Bangkok, and Manila, as well as synergies with Parkway hospitals in Singapore, Malaysia, India and Brunei. GleneaglesCRC offers a comprehensive range of services covering all stages of clinical development from bio-equivalence and bio-availability studies, to Phase I - IV clinical trials, with considerable experience in the areas of infectious disease, oncology, cardiology, gastroenterology and dermatology.
News Release Contact:
Blythe Vito
SCIREX Corporation
215-907-1330x1054
Bvito@scirex. com
# # #
